Monocytes and macrophages, implications for breast cancer migration and stem cell-like activity and treatment

Oncotarget

Volumn 6, Issue 16, 2015, Pages 14687-14699

  Ward, Rebecca ^a   Sims, Andrew H ^b   Lee, Alexander ^a   Lo, Christina ^a   Wynne, Luke ^a   Yusuf, Humza ^a   Gregson, Hannah ^a   Lisanti, Michael p ^a   Sotgia, Federica ^a   Landberg, Göran ^a,c   Lamb, Rebecca ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Breast; Macrophage; Migration; Stem cells

Indexed keywords

REACTIVE OXYGEN METABOLITE; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CARCINOGENESIS; CELL ACTIVITY; CELL DIFFERENTIATION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; MACROPHAGE; MCF 7 CELL LINE; MDA MB 231 CELL LINE; MDA MB 468 CELL LINE; MONOCYTE; STEM CELL; T47D CELL LINE; ADULT; AGED; BREAST TUMOR; CELL MOTION; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; MACROPHAGES; MIDDLE AGED; MONOCYTES;

EID: 84931050133     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4189     Document Type: Article

References (49)

1. Parkin DM, Bray F, Ferlay J and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74-108.
2. (EBCTCG) EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365:1687-1717.
3. Jensen EV and Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res. 2003; 9:1980-1989.
4. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
5. Talmadge JE and Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010; 70:5649-5669.
6. Blanco G, Holli K, Heikkinen M, Kallioniemi OP and Taskinen P. Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer. 1990; 62:142-146.
7. Chambers AF, Groom AC and MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002; 2:563-572.
8. Cardiff RD, Couto S and Bolon B. Three interrelated themes in current breast cancer research: gene addiction, phenotypic plasticity, and cancer stem cells. Breast Cancer Research. 2011; 5:6.
9. Phillips TM, McBride WH and Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006; 98:1777-1785.
10. Dean M, Fojo T and Bates S. Tumour stem cells and drug resistance. Nature Reviews Cancer. 2005; 5:275-284.
11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100:3983-3988.
12. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009; 69:1302-1313.
13. Camerlingo R, Ferraro GA, De Francesco F, Romano M, Nicoletti G, Di Bonito M, Rinaldo M, D'Andrea F and Pirozzi G. The role of CD44+/CD24-/low biomarker for screening, diagnosis and monitoring of breast cancer. Oncol Rep. 2014; 31:1127-1132.
14. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS and Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1:555-567.
15. Shaw FL, Harrison H, Spence K, Ablett MP, Simoes BM, Farnie G and Clarke RB. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J Mammary Gland Biol Neoplasia. 2012; 17:111-117.
16. Gyorki DE and Lindeman GJ. Macrophages, more than just scavengers: Their role in breast development and cancer. Anz Journal of Surgery. 2008; 78:432-436.
17. Bingle L, Brown NJ and Lewis CE. The role of tumourassociated macrophages in tumour progression: implications for new anticancer therapies. Journal of Pathology. 2002; 196:254-265.
18. Lee A, Lamb R, Lo C, Busch S, Gregson H, Bundred N and Landberg G. (2010). The effects of macrophages on in-vivo breast cancer cells, worsened patient prognosis and a reduced treatment response to letrozole and zoledronate. (Molecular and Cellular Biology: The Paterson Institute for Cancer Research, Manchester, UK), pp. 1-15.
19. Mahmoud SMA, Lee AHS, Paish EC, Macmillan RD, Ellis IO and Green AR. Tumour-infiltrating macrophages and clinical outcome in breast cancer. Journal of Clinical Pathology. 2011:1-5.
20. Classen A, Lloberas J and Celada A. Macrophage Activation: Classical vs. Alternative. Methods in Molecular Biology. 2009; 531:29-43.
21. Shabo I and Svanvik J. Expression of macrophage antigens by tumor cells. Adv Exp Med Biol. 2011; 714:141-150.
22. Kees T and Egeblad M. Innate Immune Cells in Breast Cancer - From Villains to Heroes? Journal of Mammary Gland Biology and Neoplasia. 2011; 16:189-203.
23. Mantovani A and Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Current Opinion in Immunology. 2010; 22:231-237.
24. Martinez FO, Sica A, Mantovani A and Locati M. Macrophage activation and polarization. Frontiers in Bioscience-Landmark. 2008; 13:453-461.
25. Leek RD and Harris AL. Tumor-associated macrophages in breast cancer. Journal of Mammary Gland Biology and Neoplasia. 2002; 7:177-189.
26. Winter MC, Holen I and Coleman RE. Exploring the antitumour activity of bisphosphonates in early breast cancer. Cancer Treatment Reviews. 2008; 34:453-475.
27. Rietkotter E, Menck K, Bleckmann A, Farhat K, Schaffrinski M, Schulz M, Hanisch UK, Binder C and Pukrop T. Zoledronic acid inhibits macrophage/microgliaassisted breast cancer cell invasion. Oncotarget. 2013; 4:1449-1460.
28. Sims AH, Smethurst GJ, Hey Y, Okoniewski MJ, Pepper SD, Howell A, Miller CJ and Clarke RB. The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets - improving meta-analysis and prediction of prognosis. BMC Med Genomics. 2008; 1:42.
29. Auwerx J. The human leukemia cell line, THP-1: a multifacetted model for the study of monocyte-macrophage differentiation. Experientia. 1991; 47:22-31.
30. Maess MB, Sendelbach S and Lorkowski S. Selection of reliable reference genes during THP-1 monocyte differentiation into macrophages. BMC Mol Biol. 2010; 11:90.
31. Maess MB, Wittig B, Cignarella A and Lorkowski S. Reduced PMA enhances the responsiveness of transfected THP-1 macrophages to polarizing stimuli. J Immunol Methods. 2014;402:76-81.
32. Van Dyken SJ and Locksley RM. Interleukin-4-and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol. 2013; 31:317-343.
33. Benoit M, Desnues B and Mege JL. Macrophage polarization in bacterial infections. J Immunol. 2008; 181:3733-3739.
34. Rogers TL and Holen I. Tumour macrophages as potential targets of bisphosphonates. Journal of Translational Medicine. 2011; 9:177.
35. Melani C, Sangaletti S, Barazzetta FM, Werb Z and Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Research. 2007; 67.
36. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Monkkonen H, Boccadoro M, Forni G, Musiani P, Bosia A, Cavallo F and Massaia M. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. Journal of Cellular and Molecular Medicine. 2010; 14:2803-2815.
37. Gabrilovich DI and Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology. 2009; 9:162-74.
38. Mantovani A, Sozzani S, Locati M, Allavena P and Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology. 2002; 23:549-555.
39. Garg G, Saraf S and Saraf S. Focus on Zoledronic Acid. Pharmacy On-Line. 2007.
40. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006; 10:529-541.
41. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007; 13:3207-3214.
42. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, Wong JE, Liu ET, Bergh J, Kuznetsov VA and Miller LD. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006; 66:10292-10301.
43. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two populationbased cohorts. Breast Cancer Res. 2005; 7:R953-964.
44. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006; 98:262-272.
45. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D and Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005; 365:671-679.
46. Johnson WE, Li C and Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007; 8:118-127.
47. Calza S, Hall P, Auer G, Bjohle J, Klaar S, Kronenwett U, Liu ET, Miller L, Ploner A, Smeds J, Bergh J and Pawitan Y. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006; 8:R34.
48. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL and Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100:8418-8423.
49. Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray MA, Carpenter AE, Jirstrom K, Magnusson K, Ebert BL, Ponten F, Weinberg RA and McAllister SS. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest. 2011; 121:784-799.